高级检索
当前位置: 首页 > 详情页

A Randomized Study Comparing Cisplatin/Paclitaxel Liposome vs Cisplatin/Gemcitabine in Chemonaive, Advanced Squamous NSCLC

| 认领 | 导出 |

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Shanghai Pulmonary Hospital, Tongji University, Shanghai/CN [2]Shanghai Chest Hospital, Shanghai/CN [3]Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan/CN [4]The First Affiliated Hospital of Anhui Medical University, Hefei/CN [5]Anhui Provincial Hospital, Hefei/CN [6]Fuzhou Pulmonary Hospital of Fujian, Fuzhou/CN [7]The First Affiliated Hospital of Zhengzhou University, Zhengzhou/CN [8]Henan Cancer Hospital, Zhengzhou/CN [9]Precision Medicine Center of Cancer, The Affiliated Hospital of Qingdao University, Qingdao/CN [10]Department of Medical Oncology, Hunan Cancer Hospital/ the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha/CN [11]The First Affiliated Hospital of Wenzhou Medical College, Wenzhou/CN [12]Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang/CN [13]Xiang Yang Central Hospital, Xiangyang/CN [14]Renmin Hospital of Wuhan University, Wuhan/CN [15]Jinling Hospital, Nanjing University School of Medicine, Nanjing/CN [16]Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou/CN [17]The First Hospital of Jilin University, Changchun/CN [18]Harbin Medical University Cancer Hospital, Harbin/CN [19]Weifang People’s Hospital, Weifang/CN [20]Affiliated Hospital of Hebei University, Baoding/CN [21]Shandong Cancer Hospital & Institute, Jinan/CN [22]The Third Affiliated Hospital of Kunming Medical University, Kunming/CN [23]Beijing Cancer Hospital, Beijing/CN [24]Guangzhou Medical University First Affiliated Hospital, Guangzhou/CN [25]Sichuan Cancer Hospital & Institute, Chengdu/CN [26]The Fourth People’s Hospital of Wuxi, Wuxi/CN [27]Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou/CN [28]The First Affiliated Hospital of Guangxi Medical University, Nanning/CN [29]He Second Xiangya Hospital of Central South University, Changsha/CN [30]Qingdao Municipal Hospital, Qingdao/CN [31]4Th Hospital of Hebei Medical University, Shijiazhuang/CN [32]Peking University First Hospital, Beijing/CN
出处:
ISSN:

关键词: gemcitabine advanced squamous NSCLC Paclitaxel liposome

语种:
WOS:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区:
出版当年[2021]版:
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版:
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Shanghai Pulmonary Hospital, Tongji University, Shanghai/CN
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study. [2]Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study [3]Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical study. [4]Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC [5]Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial [6]Anlotinib vs. Docetaxel in Advanced Non-Squamous NSCLC (EGFR Wild-Type) After Progression on Platinum-Based Chemotherapy: A Trial Protocol [7]Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy [8]Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial [9]Camrelizumab Plus Carboplatin and Pemetrexed as First-line Treatment for Advanced Non-squamous NSCLC: Extended Follow-up of CameL Phase 3 Trial [10]Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced non-squamous NSCLC previously treated with chemotherapy.

资源点击量:43378 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号